Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
36 participants
INTERVENTIONAL
2016-07-31
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
DP-R212 Pharmacokinetic Study
NCT02789475
DP-R208 Pharmacokinetic Study
NCT02709187
Pharmacokinetics and Safety of DWJ1451 in Healthy Adults
NCT04819932
Study of DWJ1351 in Healthy Male Volunteers
NCT02665832
Study to Evaluate the Pharmacokinetic Interaction and Safety After Multiple Oral Doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects
NCT02397538
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A group
Amlodipine and Rosuvastatin, DP-R212
DP-R212
Investigational product is prescribed to all of randomized subjects
Amlodipine
Investigational product is prescribed to all of randomized subjects
Rosuvastatin
Investigational product is prescribed to all of randomized subjects
B group
DP-R212, Amlodipine and Rosuvastatin
DP-R212
Investigational product is prescribed to all of randomized subjects
Amlodipine
Investigational product is prescribed to all of randomized subjects
Rosuvastatin
Investigational product is prescribed to all of randomized subjects
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DP-R212
Investigational product is prescribed to all of randomized subjects
Amlodipine
Investigational product is prescribed to all of randomized subjects
Rosuvastatin
Investigational product is prescribed to all of randomized subjects
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* signed the informed consent form prior to the study participation
Exclusion Criteria
* Previously donate whole blood within 60 days or component blood within 30 days
* Clinically significant allergic disease
* Taken IP in other trial within 90 days
* An impossible one who participates in clinical trial by investigator's decision including laboratory test result
19 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alvogen Korea
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DP-CTR-212-I-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.